Ocular delivery of acetylsalicylic acid by repetitive coulomb-controlled iontophoresis

Ophthalmic Research

Volumn 35, Issue 2, 2003, Pages 102-110

  Kralinger, Martina T ^a,b   Voigt, Monika ^a,c   Kieselbach, Gerhard F ^a,b   Hamasaki, Duco ^a   Hayden, Brandy C ^a   Parel, Jean Marie ^a,d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e HÔTEL DIEU   (France)

Author keywords

Acetylsalicylic acid; Coulomb controlled iontophoresis; Electroretinography; Histology; Repetitive administration

Indexed keywords

ACETYLSALICYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EYE TOXICITY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; SCLERA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; ELECTRORETINOGRAPHY; EYE; INJECTIONS, INTRAVENOUS; IONTOPHORESIS; OCULAR PHYSIOLOGY; RABBITS; TIME FACTORS;

EID: 0037233266     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069129     Document Type: Article

References (60)

1. Vane JR, Botting RM: Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47(suppl 2):78-87.
2. Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2-8.
3. Wright V: Historical overview of NSAIDs. Eur J Rheumatol Inflamm 1993;13:4-6.
4. Vane JR, Flower RJ, Botting RM: History of aspirin and its mechanism of action. Stroke 1990;21(suppl 12):12-23.
5. Higgs GA, Salmon JA, Henderson B, Vane JR: Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 1987;84:1417-1420.
6. Moncada S, Vane JR: Mode of action of aspirin-like drugs. Adv Intern Med 1979;24:1-22.
7. Flower RJ, Vane JR: Inhibition of prostaglandin biosynthesis. Biochem Pharmacol 1974;23:1439-1450.
8. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
9. Hamberg M: Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun 1972;49:720-726.
10. Higgs GA, Eakins KE, Moncada S, Vane JR: Arachidonic acid metabolism in inflammation and the mode of action of anti-inflammatory drugs. Agents Actions 1979(suppl 6):167-175.
11. Bhattacherjee P, Kulkarni PS, Eakins KE: Metabolism of arachidonic acid in rabbit ocular tissues. Invest Ophthalmol Vis Sci 1979;18:172-178.
12. Bhattacherjee P, Eakins KE: A comparison of the inhibitory activity of compounds on ocular prostaglandin biosynthesis. Invest Ophthalmol Vis Sci 1974;13:967-972.
13. Eakins KE: Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res 1977;25:483-498.
14. Bhattacherjee P, Eakins KE: Inhibition of the prostaglandin synthetase systems in ocular tissues by indomethacin. Br J Pharmacol 1974;50:227-230.
15. 2-like activity into aqueous humor after paracentesis and its prevention by aspirin. Invest Ophthalmol Vis Sci 1973;12:939-942.
16. Whitelocke RA, Eakins KE: Vascular changes in the anterior uvea of the rabbit produced by prostaglandins. Arch Ophthalmol 1973;89:495-499.
17. Preud'homme Y, Demolle D, Boeynaems JM: Metabolism of arachidonic acid in rabbit iris and retina. Invest Ophthalmol Vis Sci 1985;26:1336-1342.
18. Birkle DL, Bazan NG: Lipoxygenase- and cyclooxygenase-reaction products and incorporation into glycerolipids or radiolabeled arachidonic acid in the bovine retina. Prostaglandins 1984;27:203-216.
19. 2 changes in the retina and optic nerve of an eye with injured optic nerve. Neuroscience 1991;45:221-225.
20. Bazan HE, Birkle DL, Beuerman R, Bazan NG: Cryogenic lesion alters the metabolism of arachidonic acid in rabbit cornea layers. Invest Ophthalmol Vis Sci 1985;26:474-480.
21. Bazan HE, Birkle DL, Beuerman R, Bazan NG: Inflammation-induced stimulation of the synthesis of prostaglandins and lipoxygenase-reaction products in rabbit cornea. Curr Eye Res 1985;4:175-179.
22. 2 levels. Prostaglandins 1991;41:143-155.
23. Stjernschantz J: Autocoids and peptides in pharmacology of the eye; in Sears ML (ed): Handbook of Experimental Pharmacology. Berlin, Springer, 1984, vol 69, pp 3-11.
24. Flower RW, Blake DA: Retrolental fibroplasia: Evidence for a role of the prostaglandin cascade in the pathogenesis of oxygen-induced retinopathy in the new-born beagle. Pediatr Res 1981;15:1293-1302.
25. Flower RW, McLeod DS, Wajer SD, Sendi GS, Egner PG, Dubin NH: Prostaglandins as mediators of vasotonia in the immature retina. Pediatrics 1984;73:440-444.
26. 2 and blood-aqueous barrier disruption. Ophthalmic Res 1990;22:253-258.
27. Naveh N, Belkin M, Ben-Chaim Q, Weissman C, Treister G: Prostanoids in the vitreous of diabetic and nondiabetic human eyes with retinal detachment. Ophthalmic Res 1990;22:3-11.
28. 2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218.
29. BenEzra D: Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol 1978;86:455-461.
30. BenEzra D: Neovasculogenesis: Triggering factors and possible mechanisms. Surv Ophthalmol 1978;24:167-176.
31. 2 by tumour cells in vitro. Cancer Res 1980;40:3167-3171.
32. Miyake K, Shirasawa E, Hikita M: Hypotheses on the role of prostaglandins in the pathogenesis of epinephrine maculopathy and aphakic cystoid macular edema. Prog Clin Biol Res 1989;312:265-276.
33. Miyake K: Prostaglandins as a causative factor of the cystoid macular edema after the lens extraction. Nippon Ganka Gakkai Zasshi 1977;81:1449-1464.
34. Thomas MA, O'Grady GE, Swartz SL: Prostaglandin levels in human vitreous. Br J Ophthalmol 1985;69:275-279.
35. Martin CE, Croft KD, van Bockxmeer FM, Constable IJ: The effect of vitreous humour on prostaglandin production by cultured rabbit chorioretinal fibroblasts. Biochem Biophys Acta 1987;931:303-310.
36. Kaehler CM, Kieselbach GF, Reinisch N, Troger J, Goettinger W, Wiedermann CJ: Fibroblast growth-promoting activity in proliferative vitreoretinopathy: Antagonism by acetylsalicylic acid. Eur J Pharmacol 1994;262:261-269.
37. Jampol LM: Pharmacologic therapy of aphakic cystoid macular edema: A review. Ophthalmology 1982;89:891-897.
38. Yannuzzi LA, Landau AN, Turtz AI: Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology 1981;88:947-954.
39. Hughes L, Maurice DM: A fresh look at iontophoresis. Arch Ophthalmol 1984;102:1825-1829.
40. Voigt M, Kralinger M, Kieselbach G, Chapon P, Behar-Cohen F, Parel J-M: Aspirin coulomb controlled iontophoresis (CCI) vs intravenous injection: Posterior segment concentrations. Invest Ophthalmol Vis Sci 2000;41:S769.
41. Voigt M, Kralinger M, Kieselbach G, Anagnoste S, Parel J-M: Ocular aspirin distribution: A comparison of intravenous injection, topical and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci 2002;43:3299-3306.
42. Sing P, Maibach HI: Iontophoresis in drug delivery: Basic principles and applications. Crit Rev Ther Drug Carrier Syst 1994;11:161-213.
43. Nose I, Parel J-M, Lee W, Cohen F, De Kozak Y, Rowaan C, Paldano A, Jallet V, Soederberg P, Davis J: Ocular coulomb controlled ionto-phoresis (OCCI). Invest Ophthalmol Vis Sci 1996;37:S41.
44. Sarraf D, Lee DA: The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol 1994;10:69-81.
45. Gangarosa LP Sr, Ozawa A, Ohkido M, Shimomura Y, Hill J: Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. J Dermatol 1995;22:865-875.
46. Callegan MC, O'Callaghan RJ, Hill JM: Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet 1994;27:129-134.
47. Hill JM, Kwon BS, Burch KD, Deback J, Whang I, Jones GT, Luke B, Harp R, Shimomura Y, Hull DS, Gangarosa LP: Acyclovir and vidarabine monophosphate: Comparison of iontophoretic and intravenous administration for the treatment of HSV-1 stromal keratitis. Am J Med 1982;73:300-304.
48. Brand RM, Wahl A, Iversen PL: Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J Pharm Sci 1998;87:49-52.
49. Van der Geest R, Hueber F, Szoka FC Jr, Guy RH: Iontophoresis of bases, nucleosides, and nucleotides. Pharm Res 1996;13:553-558.
50. Asahara T, Shinomiya K, Naito T, Shiota H: Induction of genes into the rabbit eye by ionto-phoresis. Nippon Ganka Gakkai Zasshi 1999;103:178-185
51. Savoldelli M, Parel J-M, D'Hermie F, Kasner L, Pouliquen Y, De Kozak Y, Behar-Cohen F: A histologic and ultrastructural study of the rat and the rabbit eye after iontophoresis. Invest Ophthalmol Vis Sci 1998;39:S927.
52. Form DM, Auerbach R: PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218.
53. The DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-498.
54. Flower RW, Mc Leod DS, Wajer SD, Sendi GS, Egner PG, Dubin NH: Prostaglandins as mediators of vasotonia in the immature retina. Pediatrics 1984;73:440-444.
55. Salomon O, Huna-Baron R, Steinberg DM, Kurtz S, Seligsohn U: Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 1999;13:357-359.
56. Miyake K: Prostaglandins as a causative factor of the cystoid macular edema after lens extraction. Nippon Ganka Gakkai Zasshi 1977;81:1449-1464.
57. Gerli R, Gresele P, Bistoni O, Paolucci C, Lanfrancone L, Fiorucci S, Muscat C, Costantini V: Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: Induction of L-selectin shedding by a tyrosine kinase-dependent mechanism. J Immunol 2001;166:832-840.
58. Gerli R, Paolucci C, Gresele P, Bistoni O, Fiorucci S, Muscat C, Belia S, Bertotto A, Costantini V: Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 1998;92:2389-2398.
59. Yoshizumi MO, Dessouki A, Lee DA, Lee G: Determination of ocular toxicity in multiple applications of foscarnet iontophoresis. J Ocul Pharmacol Ther 1997;13:529-536.
60. Kralinger MT, Hamasaki D, Kieselbach GF, Voigt M, Parel JM: Intravitreal acetylsalicylic acid in silicone oil: Pharmacokinetics and evaluation of its safety by ERG and histology. Graefes Arch Clin Exp Ophthalmol 2001;239:208-216.